RATIONALE: Type-3 metabotropic glutamate receptor gene (GRM3) single nucleotide polymorphisms (SNPs) have been associated with cognitive performance and prefrontal cortex brain activity in chronically treated schizophrenia patients. Whether these SNPs are associated with cognitive and symptom response to antipsychotic therapy has not been extensively evaluated. OBJECTIVES: The aim of the study was to examine pharmacogenetic relationships between GRM3 and selected variants in relevant dopamine genes with changes in spatial working memory and clinical symptoms after treatment. METHODS: Sixty-one untreated first-episode schizophrenia patients were assessed before and after 6 weeks of antipsychotic pharmacotherapy, primarily consisting of risperidone. Patients' level of cognitive performance on a spatial working memory task was assessed with a translational oculomotor paradigm. Changes after treatment in cognitive and clinical measures were examined in relationship to genetic polymorphisms in the GRM3, COMT, and DRD2/ANKK1 gene regions. RESULTS: Spatial working memory performance worsened after antipsychotic treatment. This worsening was associated with GRM3 rs1468412, with the genetic subgroup of patients known to have altered glutamate activity having greater adverse changes in working memory performance after antipsychotic treatment. Negative symptom improvement was associated with GRM3 rs6465084. There were no pharmacogenetic associations between DRD2/ANKK1 and COMT with working memory changes or symptom response to treatment. CONCLUSIONS: These findings suggest important pharmacogenetic relationships between GRM3 variants and changes in cognition and symptom response with exposure to antipsychotics. This information may be useful in identifying patients susceptible to adverse cognitive outcomes associated with antipsychotic treatment and suggest that glutamatergic mechanisms contribute to such effects.
RATIONALE: Type-3 metabotropic glutamate receptor gene (GRM3) single nucleotide polymorphisms (SNPs) have been associated with cognitive performance and prefrontal cortex brain activity in chronically treated schizophreniapatients. Whether these SNPs are associated with cognitive and symptom response to antipsychotic therapy has not been extensively evaluated. OBJECTIVES: The aim of the study was to examine pharmacogenetic relationships between GRM3 and selected variants in relevant dopamine genes with changes in spatial working memory and clinical symptoms after treatment. METHODS: Sixty-one untreated first-episode schizophreniapatients were assessed before and after 6 weeks of antipsychotic pharmacotherapy, primarily consisting of risperidone. Patients' level of cognitive performance on a spatial working memory task was assessed with a translational oculomotor paradigm. Changes after treatment in cognitive and clinical measures were examined in relationship to genetic polymorphisms in the GRM3, COMT, and DRD2/ANKK1 gene regions. RESULTS: Spatial working memory performance worsened after antipsychotic treatment. This worsening was associated with GRM3rs1468412, with the genetic subgroup of patients known to have altered glutamate activity having greater adverse changes in working memory performance after antipsychotic treatment. Negative symptom improvement was associated with GRM3rs6465084. There were no pharmacogenetic associations between DRD2/ANKK1 and COMT with working memory changes or symptom response to treatment. CONCLUSIONS: These findings suggest important pharmacogenetic relationships between GRM3 variants and changes in cognition and symptom response with exposure to antipsychotics. This information may be useful in identifying patients susceptible to adverse cognitive outcomes associated with antipsychotic treatment and suggest that glutamatergic mechanisms contribute to such effects.
Authors: Su Lui; Tao Li; Wei Deng; Lijun Jiang; Qizhu Wu; Hehan Tang; Qiang Yue; Xiaoqi Huang; Raymond C Chan; David A Collier; Shashwath A Meda; Godfrey Pearlson; Andrea Mechelli; John A Sweeney; Qiyong Gong Journal: Arch Gen Psychiatry Date: 2010-08
Authors: Sonia S Kupfer; Jeffrey R Anderson; Stanley Hooker; Andrew Skol; Rick A Kittles; Temitope O Keku; Robert S Sandler; Nathan A Ellis Journal: Gastroenterology Date: 2010-07-24 Impact factor: 22.682
Authors: Kristin K Nicodemus; Bhaskar S Kolachana; Radhakrishna Vakkalanka; Richard E Straub; Ina Giegling; Michael F Egan; Dan Rujescu; Daniel R Weinberger Journal: Hum Genet Date: 2006-09-28 Impact factor: 4.132
Authors: Subroto Ghose; Kelly A Gleason; Bryan W Potts; Kelly Lewis-Amezcua; Carol A Tamminga Journal: Am J Psychiatry Date: 2009-06-01 Impact factor: 18.112
Authors: Veda N Giri; Brian Egleston; Karen Ruth; Robert G Uzzo; David Y T Chen; Mark Buyyounouski; Susan Raysor; Stanley Hooker; Jada Benn Torres; Teniel Ramike; Kathleen Mastalski; Taylor Y Kim; Rick Kittles Journal: Cancer Prev Res (Phila) Date: 2009-02-24
Authors: Lu E Jin; Min Wang; Veronica C Galvin; Taber C Lightbourne; Peter Jeffrey Conn; Amy F T Arnsten; Constantinos D Paspalas Journal: Cereb Cortex Date: 2018-03-01 Impact factor: 5.357
Authors: Nina V Kraguljac; Charity J Morgan; Meredith A Reid; David M White; Ripu D Jindal; Soumya Sivaraman; Bridgette K Martinak; Adrienne C Lahti Journal: Schizophr Res Date: 2019-01-07 Impact factor: 4.939
Authors: W C Hochberger; T Combs; J L Reilly; J R Bishop; R S E Keefe; B A Clementz; M S Keshavan; G D Pearlson; C A Tamminga; S K Hill; J A Sweeney Journal: Schizophr Res Date: 2017-05-22 Impact factor: 4.939
Authors: J M Stevenson; J L Reilly; M S H Harris; S R Patel; P J Weiden; K M Prasad; J A Badner; V L Nimgaonkar; M S Keshavan; J A Sweeney; J R Bishop Journal: Transl Psychiatry Date: 2016-02-23 Impact factor: 6.222